Alzamend Neuro, Inc.
NASDAQ Capital MarketTotal Valuation
Alzamend Neuro, Inc. carries a market capitalization of 3.61M, placing it among publicly traded companies globally.
| Market Cap | 3.61M |
| Enterprise Value | N/A |
Share Statistics
Alzamend Neuro, Inc. currently has 3.80M shares outstanding.
| Shares Outstanding | 3.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.10 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | -1.16 |
| P/OCF Ratio | -1.12 |
Financial Position
Alzamend Neuro, Inc. maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.99 |
| Quick Ratio | 1.46 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -994.43 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -171.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Alzamend Neuro, Inc.'s stock has declined approximately -69.97389% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 1.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -69.97389% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.95 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.94M, while operating income came in at -7.03M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.03M |
| Pretax Income | -7.04M |
| Net Income | -7.04M |
| EBITDA | -6.94M |
| EBIT | -7.03M |
| Earnings Per Share (EPS) | -2.27 |
Balance Sheet
Total book value stands at -64.44M, with working capital of 1.84M providing operational flexibility.
| Cash & Cash Equivalents | 2.71M |
| Total Debt | N/A |
| Net Debt | -2.71M |
| Equity (Book Value) | -64.44M |
| Book Value Per Share | -20.80 |
| Working Capital | 1.84M |
Cash Flow
Alzamend Neuro, Inc. produced -5.96M in operating cash flow over the past twelve months. After subtracting -210,000.00 in capital expenditures, free cash flow totaled -6.17M - equivalent to -1.99 per share.
| Operating Cash Flow | -5.96M |
| Capital Expenditures | -210,000.00 |
| Free Cash Flow | -6.17M |
| FCF Per Share | -1.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -82.96 |
| FCF Yield | -86.34 |
Stock Splits
Alzamend Neuro, Inc.'s most recent stock split took place on May 12, 2025 with a 9:1 split ratio.
| Last Split Date | 5/12/2025 |
| Split Ratio | 9:1 |
Scores
Alzamend Neuro, Inc. posts an Altman Z-Score of -25.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.37 |